Table 1

Baseline characteristics and DMARD therapy in all patients and in subgroups stratified by disease activity and disease duration

All patients n=1610Baseline disease activityDisease duration*
SDAI MDA n=825SDAI HDA n=785≤12months n=681>12months n=895
Age55.4 (13.5)53.9 (13.3)56.9 (13.6)55.0 (13.7)55.6 (13.5)
Female, %71.669.973.367.874.5
Disease duration, years2.0 (0.2–8.8)2.1 (0.2–9.0)1.5 (0.2–8.0)0.1 (0.0–0.4)7.3 (3.3–14.0)
Rheumatoid factor positive, %65.564.466.759.070.7
28 SJC7 (4–11)4 (2–6)11 (8–15)7 (4–11)7 (3–11)
28 TJC7 (4–12)4 (2–6)12 (8–17)8 (4–13)7 (3–11)
CRP, mg/L14 (5–31)10 (5–21)21 (8–47)13 (5–33)14 (5–30)
ESR, mm/h25 (13–41)20 (11–34)30 (16–50)26 (14–45)24 (13–40)
PhGA VAS (0–100)41.4 (16.9)32.9 (12.6)50.3 (16.3)41.6 (17.8)41.3 (16.2)
PGA VAS (0–100)52.5 (22.8)44.5 (20.8)60.9 (21.8)49.4 (22.5)54.9 (22.8)
SDAI28.3 (12.8)18.5 (4.2)38.6 (10.4)29.1 (13.4)27.8 (12.1)
CDAI26.0 (12.0)16.9 (4.2)35.5 (9.9)26.6 (12.7)25.5 (11.4)
DAS28-ESR5.2 (1.2)4.3 (0.7)6.0 (0.9)5.3 (1.2)5.1 (1.2)
DMARD therapy at baseline
MTX, monotherapy, n (%)810 (50.3%)422 (51.2%)388 (49.4%)495 (72.7%)302 (33.7%)
Other csDMARD, monotherapy, n (%)253 (15.7%)140 (17.0%)113 (14.4%)82 (12.0%)163 (18.2%)
csDMARD, combination of ≥2, n (%)190 (11.8%)92 (11.2%)98 (12.5%)47 (6.9%)139 (15.5%)
TNFi†, n (%)337 (20.9%)160 (19.4%)177 (22.5%)54 (7.9%)277 (30.9%)
Other biologic DMARD†, n (%)20 (1.2%)11 (1.3%)9 (1.2%)3 (0.4)14 (1.5%)
  • Data are presented as mean (SD) or median (25th–75th percentile) unless indicated otherwise.

  • *34 patients did not have registered disease duration at baseline.

  • †Monotherapy or in combination with conventional synthetic DMARDs.

  • CDAI, Clinical Disease Activity Index; CRP, C reactive protein; cs, conventional synthetic; DAS28, Disease Activity Score in 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sediment rate; HDA, high disease activity; MDA, moderate disease activity; MTX, methotrexate; PGA, patient global assessment; PhGA, physician global assessment; SDAI, Simplified Disease Activity Index; 28 SJC, 28-swollen joint count; 28 TJC, 28-tender joint count; TNFi, tumour necrosis factor inhibitor; VAS, visual analogue scale (0–100 mm).